Home Newsfeeds Needham Maintains Buy on Conmed, Raises Price Target to $106

Needham Maintains Buy on Conmed, Raises Price Target to $106

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and raises the price target from $90 to $106.

byBenzinga Newsdesk

November 15, 2022

1 minute read

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and raises the price target from $90 to $106.

M&A
News

Neogen Shareholders Approve All Proposals Required For Combination With 3M’s Food Safety Business

By Benzinga Newsdesk

August 17, 1:31 PM

Neogen Corporation ("Neogen") (NASDAQ:NEOG) announced that, at the special meeting of Neogen shareholders held today, Neogen shareholders voted to approve all proposals required in connection with the

MMM

Woman Takes Helm Of Quebec’s Cannabis Retail Monopoly And More Industry Changes

By Jelena Martinovic

November 2, 2:40 PM

Governmental Cannabis Retailer Welcomes First Female CEO The governmental cannabis retail monopoly in the Canadian province of Quebec, the Société québécoise du cannabis (SQDC), has a new president and CEO.

CSE:GWAY